Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Authors
Keywords
Nivolumab, Immune checkpoint inhibitor, Recurrent glioblastoma, Bevacizumab refractory
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 133, Issue 3, Pages 561-569
Publisher
Springer Nature
Online
2017-05-12
DOI
10.1007/s11060-017-2466-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
- (2017) Sith Sathornsumetee et al. NEURO-ONCOLOGY
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial
- (2016) Bogdana Suchorska et al. NEURO-ONCOLOGY
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
- (2015) M. Weller et al. CLINICAL CANCER RESEARCH
- What next for newly diagnosed glioblastoma?
- (2015) Evidio Domingo-Musibay et al. Future Oncology
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
- (2015) Kathryn M. Field et al. NEURO-ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
- (2014) W. Wick et al. CLINICAL CANCER RESEARCH
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
- (2014) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
- (2014) David E. Piccioni et al. NEURO-ONCOLOGY
- Are we done with dose-intense temozolomide in recurrent glioblastoma?
- (2014) M. J. van den Bent et al. NEURO-ONCOLOGY
- Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
- (2014) S. J. Han et al. NEURO-ONCOLOGY
- Immunotherapy advances for glioblastoma
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- Exomics and immunogenics
- (2014) Stéphane Champiat et al. OncoImmunology
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
- (2012) Roger Stupp et al. EUROPEAN JOURNAL OF CANCER
- Standards of care for treatment of recurrent glioblastoma—are we there yet?
- (2012) Michael Weller et al. NEURO-ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Salvage therapy with single agent bendamustine for recurrent glioblastoma
- (2011) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
- (2011) J. L. Clarke et al. NEURO-ONCOLOGY
- Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
- (2010) John K. Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas
- (2010) Shannon E. Fogh et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of salvage reirradiation for malignant gliomas that progress on bevacizumab
- (2009) Roy G. Torcuator et al. JOURNAL OF NEURO-ONCOLOGY
- Salvage therapy with single agent bevacizumab for recurrent glioblastoma
- (2009) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
- (2009) P. L. Nghiemphu et al. NEUROLOGY
- Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience
- (2008) Frank J. Attenello et al. ANNALS OF SURGICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now